The Evolution and Mechanisms of Linezolid Resistance in Methicillin-Resistant Staphylococcus aureus
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in healthcare settings, causing severe infections and increasing mortality rates. Clinicians often rely on antibacterial drugs like vancomycin, daptomycin, and linezolid to treat MRSA infections. However, the emergence of linezolid-resistant MRSA has become a major concern due to its potential for rapid adaptation and enhanced survival rate.
MRSA’s resistance to linezolid can develop through various mutations in ribosomal RNA and ribosomal proteins. These adaptive changes make linezolid resistance more manageable in MRSA compared to glycopeptide antibiotics. In recent studies, researchers have identified specific mutations linked to linezolid resistance, including G2576T and T2504A in the 23S rRNA gene. These mutations are crucial in understanding how MRSA evolves resistance to linezolid.
This study aimed to investigate the evolution of linezolid resistance in MRSA clinical strains under continuous exposure to linezolid. By employing phenotypic and genetic techniques, the researchers sought to uncover the underlying mechanisms driving resistance development. Their approach involved studying MRSA isolates collected from a hospital in Inner Mongolia, spanning from 2011 to 2022.
Study Methods
Collection and Identification of MRSA Isolates
Researchers collected 1032 clinical MRSA isolates from the Affiliated Hospital of Inner Mongolian Medical University between January 2011 and March 2022. The isolates were frozen until use and then subcultured on blood agar plates. They were confirmed as MRSA through MALDI-TOF MS and PCR for the mecA gene.
Antimicrobial Susceptibility Testing
Antibiotic susceptibility was assessed using VITEK-2 and broth microdilution methods. The breakpoints for sensitive (S) and resistant (R) to linezolid were set at ≤4 μg/mL and ≥8 μg/mL, respectively. Out of the 1032 strains, none was resistant to linezolid, with most having MIC values of 1 μg/mL.
Protocol of Linezolid Stress Evolution
Four MRSA isolates with varying susceptibility to linezolid were subjected to in vitro stress evolution. The isolation process involved multiple rounds of increasing linezolid concentrations until the MICs reached ≥256 μg/mL. This detailed protocol ensured the stability of the induced resistance.
The resistant strains exhibited slower growth, typical of small colony variants (SCVs), and reduced hemolytic activity. After each round of induction, the MICs were measured using broth microdilution to confirm the phenotypic resistance.
Detection of Resistance-Related Determinants
PCR was used to identify mutations in the 23S rRNA gene and ribosomal protein-encoding genes (rplC, rplD, rplV). Sequencing and phage display analysis helped in comparing the primary strains with their corresponding mutated strains. Further PCR was performed to determine the number of copies of six 23S rRNA operons (rrn1-rrn6) in the induced resistant strains.
Molecular Typing Using MLST
MLST and spa typing were conducted to differentiate the linezolid-sensitive and resistant strains. Seven housekeeping genes (arc, aroE, glpF, gmk, pta, tpi, and yqil) were amplified and sequenced. The sequences were then compared with the MLST database, acknowledging their respective allele codes.
Results
Phenotypic Resistance and Molecular Typing
Among the 1032 MRSA isolates, 8.3% were from outpatients and 91.7% from inpatients. Most isolates (53.8%) were obtained from sputum samples, followed by wound secretion (22.5%). No resistant isolates were found; however, nine strains had MIC values of 4 μg/mL.
 |
Table 2 Phenotypic Resistance and Molecular Typing results of Nine MRSA Isolates With MIC of 4 μg/mL to Linezolid |
Induction of Linezolid Resistance
Four isolates with varying MICs (0.5 μg/mL to 4 μg/mL) were induced with linezolid to monitor resistance development. The induction duration varied, ranging from 240 to 480 hours. After induction, the resistant strains exhibited stable resistance for 100 generations.
 |
Table 3 Dynamic Evolution of Phenotypic Resistance of Four MRSA Strains During Adaptive Resistance Evolution |
 |
Figure 2 Growth characteristics of the parent MRSA strains and their corresponding derivatives with linezolid resistance. Notes: F stands for “filial generation under induction by continuous linezolid”. Photographs were captured when the blood agar plates were incubated at 37°C for 24 hours. The growth rates of the induced derivates from each of the primary isolate slowed gradually as the resistance to linezolid increased. Over time, the hemolytic activities of the linezolid-resistant isolates weakened gradually (F24 and F40) or even disappeared (F52). |
Detection of Linezolid Resistance-Related Mechanisms
The study identified multiple mutations in the 23S rRNA gene contributing to linezolid resistance. The G2576T mutation was the most common, while other mutations such as C2404T, T2500A, and G2447T were found in specific strains. These findings indicated the complex mutational landscape supporting resistance in MRSA strains.
 |
Table 4 Mutations in Domain V Region of 23S rRNA Gene and Amino Acid Sequences of Ribosomal Proteins (L3 and L4) Among Four MRSA Strains and Their Resistant Derivates |
 |
Table 5 Distribution of Point Mutations in Domain V Region of 23S rRNA Gene Copies (rrn1-rrn6) |
Discussion
The study highlighted the necessity of ongoing phenotypic resistance monitoring for patients with MRSA infections treated with linezolid. Differences in MIC values between VITEK-2 and broth microdilution methods suggest the importance of using precise methodologies for resistance detection.
The emergence of linezolid resistance demonstrates the adaptive capability of MRSA in response to therapeutic pressures. The genetic mechanisms contributing to resistance, including mutations in the 23S rRNA gene, play a significant role in this adaptive process.
The study’s findings provide valuable insights into the resistance mechanisms of MRSA and underscore the importance of developing strategies to mitigate the spread of resistant strains. Monitoring and addressing resistance development is crucial for effective clinical management of MRSA infections.
Conclusion
Understanding the mechanisms underlying linezolid resistance in MRSA is essential for informed clinical decision-making. The study’s findings contribute to the broader knowledge base on MRSA resistance and emphasize the importance of continuous surveillance and adaptive antibiotic stewardship. Further research into resistance mechanisms and prevention strategies is warranted to address the evolving threat of drug-resistant bacteria.
Call to Action
We encourage you to share your thoughts on this study and its implications. Share your comments, questions, or feedback below. Join our community to stay informed on the latest developments in medical research and advancements in healthcare.
